Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD
This study is looking at how obstructive sleep apnea (OSA) and chronic obstructive pulmonary disease (COPD) together might affect thinking skills, sleepiness, and quality of life in elderly Veterans. Researchers want to see if having both conditions, called 'Overlap Syndrome,' makes these problems worse compared to having just one condition. They will also investigate if treatments like CPAP (continuous positive airway pressure) alone, or CPAP combined with NIPPV (non-invasive positive pressure ventilation) and/or oxygen, can improve these issues. You might be able to join if you are an elderly Veteran (ages 60-89) with moderate-to-severe OSA and moderate-to-severe COPD. The study aims to see if these treatments improve neurocognitive function, sleepiness, and quality of life after 3 months.
- Study design
- This is an interventional study planning to enroll 108 participants. It compares different treatment approaches for sleep apnea and COPD.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary outcomes, such as neurocognitive function, sleepiness, and quality of life, will be measured at 3 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Susmita Chowdhuri, MD MS · PRINCIPAL_INVESTIGATOR · John D. Dingell VA Medical Center, Detroit, MI
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Neurocognitive functionChange from baseline neurocognitive function at 3 months
The neurocognitive test - Trails A test will be administered to evaluate attention and psychomotor function. This score is adjusted for age, race, gender, and years of education. Scored on a Standard scale of 100 +/- 15 for normal ranges, above 115 is above average, below 85 is considered below average.
- SleepinessChange from baseline sleepiness at 3 months
Epworth Sleepiness Scale (ESS) score will be measured. This score is on a scale of 0-24, where a higher value indicates a worse outcome.
- Quality of life (Short-Form survey)Change from baseline quality of life at 3 months
Quality of Life (Qol) Questionnaires: QoL will be assessed using the Short-Form survey (SF-12). There are two subscale domain scores (Physical Health Composite Score-PCS and Mental Health Composite Score-MCS). These are on a scale of 0-100, where higher values indicate a better outcome.
- Neurocognitive testChange from baseline at 3 months
The neurocognitive test - Trails B test will be administered to evaluate attention and psychomotor function. This score is adjusted for age, race, gender, and years of education. Scored on a Standard scale of 100 +/- 15 for normal ranges, above 115 is above average, below 85 is considered below average.
- Neurocognitive test (Paced Auditory Serial Addition Test)Change from baseline at 3 months
The neurocognitive test: Paced Auditory Serial Addition Test (PASAT) will be administered to evaluate vigilance and executive function. The PASAT is recorded as the total number of correct responses (from 0-60), or the percent of correct responses out of 60 (from 0-100), where a higher value is a better outcome.
- Neurocognitive test (Stroop Color-Word Interference)Change from baseline at 3 months
The neurocognitive test: Stroop color-word interference test will be administered to evaluate executive function. This score is adjusted for age, and years of education. Scored on a Standard scale of 100 +/- 15 for normal ranges, above 115 is above average, below 85 is considered below average.
- Neurocognitive test (DIGIT test)Change from baseline at 3 months
The neurocognitive DIGIT test will be administered to evaluate short-term and working memory. This score is adjusted for age. Scored on a Standard scale of 100 +/- 15 for normal ranges, above 115 is above average, below 85 is considered below average.
- Neurocognitive test (Wechsler Abbreviated Scale of Intelligence)Change from baseline at 3 months
The neurocognitive test: abbreviated Wechsler Abbreviated Scale of Intelligence (WASI) will be administered to evaluate verbal comprehension and working memory. This score is adjusted for age. Scored on a Standard scale of 100 +/- 15 for normal ranges, above 115 is above average, below 85 is considered below average.
- Quality of life (Functional Outcomes of Sleep Questionnaire)Change from baseline quality of life at 3 months
Quality of Life (Qol) Questionnaires: Disease specific QoL will be assessed using the Functional Outcomes of Sleep Questionnaire (FOSQ)-10. There are 5 subscale domains of the FOSQ (General Productivity, Social Outcome, Activity Level, Vigilance, and Intimate Relationships and Sexual Activity). There all range from 0-20, where a higher value is a better outcome. The total FOSQ is the sum of these subscale domains and ranges from 0-100, where a higher value is a better outcome.
- Quality of life (St. George's Respiratory Questionnaire)Change from baseline quality of life at 3 months
Quality of Life (Qol) Questionnaires: Disease specific QoL will be assessed using the St. George's Respiratory Questionnaire (SGRQ). The SGRQ has three subscale domains (Symptoms, Activity, and Impacts), which range from 0-100, where a higher value indicates a worse outcome. The total SGRQ is the average of these subscale domains and is on a scale of 0-100, where a higher value is a worse outcome.